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An immunohistochemical analysis for E(epithelial)-cadherin and N(neural)-cadherin expression in relation to tumour angiogenesis
was performed in 150 patients with non-small-cell lung cancer (NSCLC). In all, 71 carcinomas (47.3%) were E-cadherin-negative.
Epithelial-cadherin-negative tumours had lymph node metastases significantly more frequently than E-cadherin-positive tumours
(P¼0.0100). On the other hand, 46 carcinomas (30.7%) were N-cadherin-positive. Regarding tumour vascularity, there was no
significant correlation between E-cadherin expression and tumour vascular. In contrast, the frequency of hypervascular tumours was
significantly higher for N-cadherin-positive carcinomas than for N-cadherin-negative carcinomas (P¼0.0373). Regarding prognosis,
the 5-year survival rate of patients with E-cadherin-negative NSCLCs was significantly lower than that of patients with E-cadherin-
positive NSCLCs (P¼0.0146). In contrast, of the patients with large cell carcinomas, the 5-year survival rate of patients with
N-cadherin-positive tumours was significantly lower than that of patients with N-cadherin-negative tumours (P¼0.0013). A
multivariate analysis demonstrated that E-cadherin status (P¼0.0339) and tumour vascularity (P¼0.0295) were significant indicators
for survival. In conclusion, E-cadherin expression and tumour vascularity are significant prognostic factors of NSCLC patients.
Furthermore, N-cadherin expression is associated with tumour angiogenesis, and its expression is one of prognostic factors of
patients with large cell carcinomas. Thus, N-cadherin also might play a specific role in undifferentiated large cell carcinomas.
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It is widely accepted that malignant tumours are caused by the
accumulation of genetic alterations, which could reflect the
biological behaviour of tumours (Cordon-Cardo, 1995). In
particular, metastasis is specific for malignant tumours, and the
control of tumour metastasis is one of the most important
problems in the design of therapies for cancer patients. Its initial
step is the escape of cells from the primary tumours, which is
considered to be dependent on the status of various adhesion
molecules, including cadherins, integrins, selectins, and the
immunoglobulin superfamily (Pignatelli and Vessey, 1994).
Cadherins are transmembrane glycoproteins that function for
calcium-dependent homophilic cell–cell adhesion (Takeichi,
1991). They include several subclasses, such as E (epithelial)-
cadherin, N (neural)-cadherin, P (placental)-cadherin and so on.
Among these cadherins, E-cadherin is widely expressed in normal
epithelial tissues and is linked to the actin cytoskeleton by the
catenins (Aberle et al, 1996). Experimental studies have demon-
strated that E-cadherin acts as a metastatic suppressor gene
(Frixen et al, 1991; Mbalaviele et al, 1996). Previous clinical studies
also have revealed that the functional disruption of E-cadherin is
associated with tumour dedifferentiation and metastasis in various
human cancers including non-small-cell lung cancers (NSCLCs)
(Shibanuma et al, 1998; Sulzer et al, 1998; Liu et al, 2001).
On the other hand, N-cadherin is expressed mainly in the
nervous system and in mesenchymal cells, such as myocytes and
fibroblasts (Hatta et al, 1987). And its expression is associated with
a variety of morphogenic events and angiogenesis during
development (Hatta and Takeichi, 1986; Blaschuk and Rowlands,
2000). Thus, the function of N-cadherin is suggested to be different
from that of E-cadherin. Furthermore, recent studies have
demonstrated that N-cadherin expression in tumour tissues is
associated with tumour progression, such as epithelial–mesen-
chymal transitions (Birchmeier et al, 1996), motility, and
metastasis (Nieman et al, 1999; Hazan et al, 2000; Li et al, 2001).
In addition, several studies on human cancers have reported the
presence of the cadherin switching, from E-cadherin to N-cadherin
(Hsu et al, 1996; Tomita et al, 2000).
However, despite of the accumulation of these results regarding
N-cadherin, only a few clinical studies on N-cadherin expression in
human cancers were reported (Yanagimoto et al, 2001), and its
true function in human cancers is still unknown. Therefore, to
clarify the function of N-cadherin in NSCLCs, we performed a
retrospective clinical study on N-cadherin expression and E-
cadherin expression by immunohistochemistry. In addition,
because the tumour angiogenesis was also reported to be essential
to tumour growth and metastasis (Folkman, 1990, 1995), we
evaluated intratumoural microvessel density (IMD) using anti-
CD34 monoclonal antibody to study the correlation between N-
cadherin expression and tumour angiogenesis (Matsuyama et al,
1998). Received 13 January 2003; accepted 25 February 2003
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Clinical characteristics of patients
From January 1993 to February 1999, NSCLC patients who
underwent surgery at the Second Department of Kagawa Medical
University were studied. Tumour-node-metastasis (TNM) staging
designations were made according to the international postsurgical
pathological staging system. Since advanced stage lung cancer
(stage IV) involves several complicated factors and these primary
tumour specimens are difficult to obtain by surgical resection,
these patients were excluded from this study. In total, 150 patients
with lung cancer up to stage IIIB, which included 86 patients with
adenocarcinoma, 50 patients with squamous cell carcinoma, and
14 patients with large cell carcinoma which is defined as
undifferentiated NSCLC without the component of squamous cell
carcinoma, adenocarcinoma (Travis et al, 1999), were investigated.
The patients’ clinical records and histopathological diagnoses were
fully documented. This report includes follow-up data as of 10
September 2002. The median follow-up period for all patients was
41.1 months.
Immunohistochemical staining of E-cadherin, N-cadherin,
and CD34
We used a mouse polyclonal antibody for E-cadherin (Clone
HECD-1, Takara, Otsu, Japan) diluted at 1:400, a mouse
monoclonal antibody for N-cadherin (clone 32, BD Bioscience,
Franklin Lakes, NJ, USA) diluted at 1:1000, and a mouse
monoclonal antibody for CD34 (NU-4A1, Nichirei Corporation,
Tokyo, Japan) diluted at 1:10.
Formalin-fixed paraffin-embedded tissue specimens were cut
into 4-mm sections and mounted on poly-L-lysine-coated slides.
The sections were deparaffinised and rehydrated. The slides were
then heated in a microwave for 10min in a 10-mmoll
 1 citrate
buffer solution at pH 6.0, and cooled to room temperature for
20min. After quenching the endogenous peroxidase activity with
0.3% H2O2 (in absolute methanol) for 30min, the sections were
blocked for 2h at room temperature with 5% bovine serum
albumin. Subsequently, duplicate sections were incubated over-
night with the primary specific antibodies for E-cadherin, N-
cadherin, and CD34, respectively. The slides were then incubated
for 1h with biotinylated anti-mouse IgG (Vector Laboratories Inc.,
Burlingame, CA, USA). The sections were incubated with the
avidin–biotin–peroxidase complex (Vector Laboratories Inc.) for
1h, and the antibody binding was visualised with 3,30-diamino-
benzidine tetrahydrochloride. Finally, the sections were counter-
stained with Mayer’s haematoxylin (Figure 1). Normal bronchus
epithelium and normal mucosal glands within the tumour sections
were used as positive internal controls for staining of E-cadherin.
Sections of resected lung tumours known to express N-cadherin
were used as positive controls for staining of N-cadherin. Sections
incubated with normal mouse IgG served as negative reaction
controls for staining of E-cadherin and N-cadherin.
All of the immunostained sections were reviewed by two
pathologists who had no knowledge of the patients’ clinical status.
Patients with contradictory scores were reevaluated jointly on a
second occasion and consensus was reached. For the evaluation of
immunostaining of E-cadherin and N-cadherin, in cases with
multiple areas of low intensity, five areas selected at random were
scored; in sections where all of the staining appeared intense, one
random field was selected. At least 200 tumour cells were scored
per  40 field. When X50% of the tumour cells in a given
specimen were positively stained for E-cadherin, the sample was
classified as E-cadherin-positive. When o50% of the cells were
stained, it was classified as E-cadherin-negative. In addition, when
X20% of the tumour cells in a given specimen were positively
stained for N-cadherin, the sample was classified as N-cadherin-
positive. When o20% of the cells were stained, it was classified as
N-cadherin-negative.
For microvessel quantification, the three most highly vascu-
larised areas detected by CD34 immunostaining were initially
selected under the  40 field, and a  200 field (0.785mm
2 per
field) was used to count vessels in each of these areas (Figure 1F).
Vessels of a calibre larger than approximately eight red blood cells
and vessels with thick muscular walls were excluded from the
count. Single endothelial cells or clusters of endothelial cells, with
or without lumen, were considered to be individual vessels. Finally,
the average of three  200 field counts was recorded as the IMD.
Tumours with IMD X90 were classified as hypervascular, while
tumours with IMD o90 were classified as hypovascular.
Statistical analysis
The overall cancer-specific survival was defined from the date of
the operation to the date of cancer-related death. The statistical
differences in E-cadherin and N-cadherin expression in relation to
several other clinical and pathological parameters including IMD
were assessed by the w
2 test and the t-test. The Kaplan–Meier
method was used to estimate the probability of overall survival as
function of time, and differences in the survival of subgroups of
patients were compared with Mantel’s log-rank test. Cox’s
proportional-hazards regression model was used to study the
effects of different variables on survival. All P-values were based on
two-tailed statistical analysis and a P-value o0.05 was considered
to indicate statistical significance.
RESULTS
Epithelial-cadherin expression in NSCLCs
Normal bronchus epithelium and normal mucosal glands had
positive membranous expression of E-cadherin. Intratumoural
E-cadherin staining also appeared in the form of a membranous
staining pattern, with or without cytoplasmic staining (Figure 1A,
B). Of the 150 tumours studied, 79 carcinomas (52.7%) were
E-cadherin-positive, and 71 carcinomas (47.3%) were E-cadherin-
negative (Table 1). Of the 86 adenocarcinomas, 36 tumours
(41.9%) were E-cadherin-negative. Of the 50 squamous cell
carcinomas, 25 tumours (50.0%) were E-cadherin-negative. Of
the 14 large cell carcinomas, 10 tumours (71.4%) were E-cadherin-
negative. The frequency of E-cadherin-negative tumours was likely
to be greater in large cell carcinoma than any other tumour
histology. Furthermore, E-cadherin-negative tumours had lymph
node metastases significantly more frequently than E-cadherin-
positive tumours (39.4 vs 20.3%, P¼0.0100) (Table 1). In addition,
advanced stage tumours were significantly more frequent in
E-cadherin-negative tumours than in E-cadherin-positive tumours
(53.5 vs 32.9%, P¼0.0378).
Neural-cadherin expression in NSCLCs
Intratumoural N-cadherin staining also appeared in the form of a
membranous staining pattern, with or without cytoplasmic
staining. Of the 150 tumours, 46 carcinomas (30.7%) were
N-cadherin-positive, and 104 carcinomas (69.3%) were N-cadherin-
negative (Figure 1C–E and Table 1). Of the 86 adenocarcinomas,
31 tumours (36.0%) were N-cadherin-positive. Of the 50 squamous
cell carcinomas, 10 tumours (20.0%) were N-cadherin-positive.
Of the 14 large cell carcinomas, five tumours (35.7%) were
N-cadherin-positive. There was no significant relation between
N-cadherin expression status and tumour histology. In addition,
there was no significant relation between N-cadherin expression
status and other patient prognostic factors, such as tumour status,
nodal status, pathological stage, and tumour differentiation
(Table 1).
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expression
With respect to 150 NSCLCs, 28 tumours (35.4%) were N-
cadherin-positive among the 79 E-cadherin-positive carcinomas,
while 18 tumours (25.4%) were N-cadherin-positive among the 71
E-cadherin-negative carcinomas. There was no significant relation
between N-cadherin expression and E-cadherin expression in
NSCLCs. However, regarding 14 undifferentiated large cell
carcinomas, only one tumour (25.0%) was N-cadherin-positive
among four E-cadherin-positive tumours, while four tumours
(40.0%) were N-cadherin-positive among 10 E-cadherin-negative
tumours.
Tumour vascularity in NSCLCs
The IMD in the 150 NSCLCs ranged from 24.0. to 394.7, with a
mean of 110.6765.3. In all, 82 carcinomas (54.7%) were
hypervascular, and 68 carcinomas (45.3%) were hypovascular
(Table 1). Regarding tumour histology, of the 86 adenocarcinomas,
58 tumours (67.4%) were hypervascular. Of the 50 squamous cell
carcinomas, 17 tumours (34.0%) were hypervascular. Of the 14
large cell carcinomas, seven tumours (50.0%) was hypervascular.
The frequency of hypervascular tumours in adenocarcinomas was
significantly greater than that in squamous cell carcinomas
(P¼0.0007). However, there were no significant correlation
between IMD and other prognostic factors, such as tumour status,
nodal status, tumour differentiation.
Relation between cadherin expressions and tumour
vascularity
With respect to E-cadherin status, of the 79 E-cadherin-positive
carcinomas, 46 tumours (58.3%) were hypervascular; of the 71
E-cadherin-negative carcinomas, 36 tumours (50.7%) were hyper-
vascular. There was no significant correlation between E-cadherin
expression and tumour vascularity.
Regarding N-cadherin status, of the 46 N-cadherin-positive
carcinomas, 31 tumours (67.4%) were hypervascular; of the 104
N-cadherin-negative carcinomas, 51 tumours (49.0%) were
hypervascular. The frequency of hypervascular tumours was
significantly higher for N-cadherin-positive carcinomas than
for N-cadherin-negative carcinomas (P¼0.0373; Figure 2). With
respect to tumour histology, of the 86 adenocarcinomas, the
frequencies of hypervascular tumours were 74.2% in N-cadherin-
positive carcinomas, 63.6% in N-cadherin-negative carcinomas. Of
the 50 squamous cell carcinomas, the frequencies of hypervascular
tumours were 50.0% in N-cadherin-positive carcinomas, 30.0% in
Figure 1 Immunohistochemical staining of human NSCLC tissues using
the avidin–biotin–peroxidase complex procedure (original magnification,
 100). (A) An E-cadherin-positive carcinoma. (B) An E-cadherin-negative
carcinoma. (C), (D) N-cadherin-positive carcinomas. (E) A N-cadherin-
negative carcinoma. (F) Intratumoural microvessel detected by anti-CD34
antibody in a carcinoma.
Table 1 Distribution of 150 NSCLC patients according to E-cadherin, N-cadherin status, and tumour vascularity
E-cadherin N-cadherin Tumour vascularity
Variables n Positive Negative P-value Positive Negative P-value Hypervascular Hypovascular P-value
Tumour status
T1 62 36 26 0.1629 20 42 0.9245 39 23 0.0540
T2 50 27 23 16 34 20 30
T3 7 1 6 2 5 3 4
T4 31 15 16 8 23 20 11
Nodal status
N0 106 63 43 0.0100 35 71 0.3265 58 48 0.9847
N1, N2, N3 44 16 28 11 33 24 20
Pathological stage
Stage I 86 53 33 0.0378 28 58 0.3198 45 41 0.6656
Stage II 15 4 11 3 12 8 7
Stage IIIA 18 7 11 8 10 9 9
Stage IIIB 31 15 16 7 24 20 11
Differentiation
Well 54 32 22 0.2815 17 37 0.9859 37 17 0.0375
Moderately 50 27 23 15 35 23 27
Poorly 46 20 26 14 32 22 24
Histology
Adenocarcinoma 86 50 36 0.1088 31 55 0.1344 58 28 0.0070
Squamous cell carcinoma 50 25 25 10 40 17 33
Large cell carcinoma 14 4 10 5 9 7 7
Total number of patients 150 79 71 46 104 82 68
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the frequencies of hypervascular tumours were 60.0% in N-
cadherin-positive carcinomas, 44.4% in N-cadherin-negative
carcinomas.
Overall survival of NSCLC patients in relation
to E-cadherin status, N-cadherin status, and
tumour vascularity
The 5-year survival rates of 150 NSCLC patients according to
E-cadherin status, N-cadherin status and tumour vascularity are
shown in Table 2. With respect to E-cadherin status, the 5-year
survival rate of patients with E-cadherin-negative NSCLCs was
significantly lower than that of patients with E-cadherin-positive
NSCLCs (45.4 vs 64.4%, P¼0.0146, Figure 3A). Especially, the
5-year survival rate of patients with E-cadherin-negative T1 tumours
was significantly lower than that of patients with E-cadherin-
positive T1 tumours (79.1 vs 59.8%, P¼0.0328, Figure 3B).
In contrast, there was no significant difference in the 5-year
survival rate between patients with N-cadherin-positive NSCLCs
and patients with N-cadherin-negative NSCLCs (59.6 vs 54.0%).
However, of the 14 patients with undifferentiated large cell
carcinomas, the 5-year survival rate of patients with N-cadherin-
positive tumours was significantly lower than that of patients with
N-cadherin-negative tumours (0.0 vs 55.6%, P¼0.0013, Figure 3C).
With respect to tumour vascularity, the 5-year survival rate of
patients with hypervascular NSCLCs was significantly lower than
that of patients with hypovascular NSCLCs (50.8 vs 62.2%,
P¼0.0378, Figure 3D). Regarding tumour histology, the 5-year
survival rate of patients with hypervascular squamous cell
carcinomas was significantly lower than that of patients with
hypovascular squamous cell carcinomas (44.1 vs 68.3%,
P¼0.0349).
A multivariate analysis using Cox proportional-hazards regres-
sion model was performed to evaluate prognostic factors for
NSCLC patients, as shown in Table 3. Epithelial-cadherin status
(hazard ratio¼1.736, P¼0.0339) and tumour vascularity (hazard
ratio¼1.785, P¼0.0295) were significant indicators for survival of
NSCLC patients. With respect to tumour histology, tumour
vascularity was also a significant indicator for survival of patients
with squamous cell carcinomas (hazard ratio¼5.529, P¼0.0053),
and patients with large cell carcinomas (hazard ratio¼24.815,
P¼0.0312).
DISCUSSION
The cadherins are members of a large family of transmembrane
glycoproteins that mediate calcium dependent, homophilic cell–
cell adhesion and play an important role in the maintenance of
normal tissue architecture (Takeichi, 1990). Among this family, E-
cadherin is widely expressed in normal epithelial cells. Numerous
studies have demonstrated the importance of the E-cadherin/
catenin complex in maintaining the normal phenotype of epithelial
cells (Frixen et al, 1991; Mbalaviele et al, 1996). Although the
actual mechanisms responsible for its functional disruption in
human cancers are still not fully clarified (Blaschuk et al, 1995;
Nawrocki et al, 1998), their dysfunction causes dedifferentiation
and invasive tumours. In a previous experimental study, invasive
fibroblastic-like carcinoma cells could be converted to a non-
invasive phenotype by transfection of E-cadherin cDNA (Frixen
et al, 1991). Previous clinical studies in human cancers, including
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Figure 2 Tumour vascularity in relation to N-cadherin status in NSCLCs.
Table 2 Five-year survival rate of 150 NSCLC patients according to E-cadherin, N-cadherin status, and tumour vascularity
E-cadherin N-cadherin Tumour vascularity
Variables Positive Negative P-value Positive Negative P-value Hypervascular Hypovascular P-value
Tumour status
T1 79.1 59.8 0.0328 76.8 68.5 0.7681 70.0 72.4 0.6472
T2 59.9 45.5 0.4792 45.0 57.2 0.5120 40.0 62.5 0.0106
T3 0.0 25.0 0.7741 0.0 33.3 0.0389 0.0 50.0 0.4547
T4 40.4 24.1 0.2268 60.0 22 0.0909 31.8 37.9 0.9706
Nodal status
N0 73.2 58.4 0.1863 71.3 65.7 0.5415 61.0 76.2 0.0613
N1,N2,N3 31.1 25.2 0.2680 24.2 27.7 0.6718 26.3 26.5 0.2061
Pathological stage
Stage I 78.4 65.6 0.3910 74.9 72.9 0.6786 70.4 77.8 0.3797
Stage II 50.0 40.0 0.6728 33.3 45.5 0.4972 25.0 66.7 0.1021
Stage IIIA 21.4 20.0 0.4972 18.8 22.2 0.4935 22.2 16.7 0.2155
Stage IIIB 40.4 24.1 0.2268 53.6 25.9 0.2244 31.8 37.9 0.9706
Differentiation
Well 80.7 57.1 0.0284 87.5 63.7 0.1619 68.6 75.0 0.4029
Moderately 62.2 47.1 0.3806 27.6 64.2 0.1245 41.1 67.3 0.0285
Poorly 34.8 32.8 0.4907 53.3 33.4 0.4948 33.3 44.9 0.1870
Histology
Adenocarcinoma 64.3 46.8 0.0777 68.5 51.1 0.1518 57.3 57.1 0.8660
Squamous cell carcinoma 68.3 50.4 0.1619 60.0 58.0 0.4981 44.1 68.3 0.0349
Large cell carcinoma 50.0 30.0 0.4934 0.0 55.6 0.0013 14.3 57.1 0.0535
Total 64.4 45.4 0.0146 59.6 54.0 0.6596 50.8 62.2 0.0378
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Figure 3 (A) Overall survival of 150 patients with NSCLC in relation to their E-cadherin status. (B) Overall survival of 62 patients with T1 NSCLC in
relation to their E-cadherin status. (C) Overall survival of 14 patients with large cell carcinoma in relation to their N-cadherin status. (D) Overall survival of
150 patients with NSCLC in relation to their tumour vascularity.
Table 3 Multivariate regression analysis in predicting survival of 150 NSCLC patients
Histology Non-small-cell lung cancer Adenocarcinoma Squamous cell carcinoma Large cell carcinoma
Variables
Assigned
score
Hazard
ratio
P-value Hazard
ratio
P-value Hazard
ratio
P-value Hazard
ratio
P-value
E-cadherin
Positive 0 1.736 0.0339 1.389 0.3503 2.662 0.0912 0.111 0.2586
Negative 1
Tumour vascularity
Hypovascular 0 1.785 0.0295 1.121 0.7693 5.529 0.0053 24.815 0.0312
Hypervascular 1
Tumour status
T1 1 1.399 0.0013 1.352 0.0194 1.756 0.0816 7.020 0.0374
T2 2
T3 3
T4 4
Nodal status
N0 0 1.829 o0.0001 1.719 0.0007 2.916 0.0162 15.526 0.0160
N1, N2, N3 1
Smoking
Nonsmoker 0 1.485 0.1860 1.534 0.2838 2.461 0.3222 23.088 0.0834
Smoker 1
Age (year)
o60 0 0.898 0.7386 0.681 0.3459 2.034 0.5356 19.941 0.0530
X60 1
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catenin complex is associated with dedifferentiation (Bohm et al,
1994), lymph node metastasis (Sulzer et al, 1998), and a poor
prognosis (Sulzer et al, 1998). The present study has also revealed
that decreased expression of E-cadherin is associated with lymph
node metastasis and a poor prognosis in NSCLC patients. Thus, E-
cadherin acts as a metastatic suppressor gene in human NSCLCs.
Consistent with these results, E-cadherin promotes tight cell–
cell adhesion in a zipper-like fashion, restricting cell movement.
On the other hand, recent experimental studies have demonstrated
that N-cadherin could promote a dynamic adhesion state. Neural-
cadherin is responsible for the interaction between endothelial
cells and other surrounding cell types expressing N-cadherin such
as vascular smooth muscle cells and pericytes (Navarro et al,
1998). This kind of adhesion of N-cadherin was suggested to play
important roles in various biological behaviours, including
morphogenesis (Takeichi, 1991) and angiogenesis (Gerhardt et al,
1999, 2000) during development and epithelial–mesenchymal
transition during tumour progression (Islam et al, 1996; Tran
et al, 1999).
With respect to tumour progression, N-cadherin expression
could mediate an epithelial–mesenchymal transition and angio-
genesis. At first, the epithelial–mesenchymal transition is asso-
ciated with typical for some carcinoma cells late in tumour
progression and correlated with metastatic potential (Birchmeier
et al, 1996). In an experimental study, transfection of antisense
N-cadherin into a cancer cell line with a scattered fibroblastic
phenotype resulted in reversion to a normal-appearing squamous
epithelial cell, interestingly, with increased E-cadherin expression
(Islam et al, 1996). In addition, transfection of N-cadherin into a
normal-appearing squamous epithelial cell line resulted in a
scattered fibroblastic phenotype, with downregulation of E-
cadherin. Another study also revealed that a N-cadherin-positive
carcinoma cell line displayed an invasive potential after intraper-
itoneal injection into SCID mice (Tran et al, 1999).
Recently, basic studies have shown the presence of the
interactions between N-cadherin and fibroblast growth factor
(FGF) receptor (Doherty and Walsh, 1996; Saffell et al, 1997).
Hazan et al. (2000) demonstrated that treatment with FGF-2
induced N-cadherin-expressing breast carcinoma cells into a more
invasive phenotype, with upregulation of matrix metalloproteinase
MMP-9. Other experimental studies have also shown that
transfection of N-cadherin can promote motility in human cancer
cell lines (Nieman et al, 1999; Li et al, 2001).
On the other hand, N-cadherin expression was reported to
mediate angiogenesis during development. N-cadherin-expressing
cells can interact with N-cadherin-expressing vascular endothelial
cells during development (Gerhardt et al, 1999, 2000). Then, the
interaction of N-cadherin and FGF receptor promotes the FGF-2
signal pathway, which was reported to induce vascular endothelial
growth factor expression (Seghezzi et al, 1998). Therefore, N-
cadherin-expressing tumour cells might induce angiogenesis
through the interaction with N-cadherin-expressing vascular
endothelial cells during tumour progression. In addition, the
tumour angiogenesis is also essential to tumour growth and
metastasis (Folkman, 1990, 1995).
Despite of the accumulation of these results regarding N-
cadherin, only a few clinical studies on N-cadherin expression in
human cancers were reported (Soler et al, 1997; Yanagimoto et al,
2001). Therefore, we performed the present clinical study on the
expression of N-cadherin and E-cadherin in NSCLC patients.
At first, our present study revealed that N-cadherin expression
in NSCLCs is significantly associated with tumour vascularity. This
is the first clinical report demonstrating a correlation between
N-cadherin expression and angiogenesis in human cancers.
Especially, the frequencies of hypervascular tumours in N-
cadherin-expressing tumours were likely to be higher than that
in N-cadherin-negative tumours, among squamous cell carcinoma
(50.0 vs 30.0%), and among large cell carcinoma (60.0 vs 44.4%). In
addition, of the large cell carcinomas, the frequency of N-cadherin-
positive tumours was likely to be greater in E-cadherin-negative
tumours than in E-cadherin-positive tumours (40.0 vs 25.0%).
Furthermore, among the large cell carcinomas, survival of patients
with N-cadherin-positive tumours was significantly lower than that
of patients with N-cadherin-negative tumours. However, there was
no significant correlation between N-cadherin status and lymph
node metastasis.
These results might suggest that in some populations of
NSCLCs, from well-differentiated squamous cell carcinomas to
undifferentiated large cell carcinomas, inactivation of E-cadherin
is an early event in the tumour progression, and activation of the
inappropriate cadherin, such as N-cadherin, would be a subse-
quent event, which could promote angiogenesis and poor survival.
This concept of cadherin switching (Cavallaro et al, 2002) has been
reported in some kinds of human cancers, such as melanoma (Hsu
et al, 1996) and prostate cancer (Tomita et al, 2000). In the present
study, however, there was no significant inverse correlation
between E-cadherin expression and N-cadherin. This might be
partly because undifferentiated carcinoma is relatively rare among
NSCLCs.
On the other hand, there was no such a relation regarding N-
cadherin expression in adenocarcinomas. Thus, different cellular
mechanisms might be responsible in the progression of squamous
cell carcinomas and adenocarcinomas (Bohm et al, 1994). In the
present study, although tumour vascularity was a significant
prognostic factor both in patients with squamous cell carcinoma
and in patients with large cell carcinoma, there was no significant
difference in the survival of patients with adenocarcinoma in
relation to tumour vascularity. This finding might be partly
because most of adenocarcinomas were hypervascular. In addition,
reduced expression of integrin, another kind of adhesion
molecules, is associated with the prognosis of patients with
adenocarcinoma of the lung (Adachi et al, 1998).
In conclusion, the present study of NSCLC patients has
demonstrated that E-cadherin expression and tumour vascularity
are significant prognostic factors of NSCLC patients. Furthermore,
N-cadherin expression is associated with tumour angiogenesis,
and its expression is one of the prognostic factors of patients with
undifferentiated large cell carcinomas. Thus, N-cadherin also
might play a specific role in NSCLCs, especially in undifferentiated
large cell carcinomas.
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